medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-13-14-20medalphabet-3715Research ArticleСтатьиАнемия хронических заболеванийAnemia of chronic diseaseshttps://orcid.org/0000-0002-4293-3285ОрловаН. В.OrlovaN. V.

Орлова Наталья Васильевна - д. м. н., проф., проф. кафедры факультетской терапии педиатрического факультета.

Москва

Orlova Natalia V. - DM Sci (habil.), professor at Dept of faculty therapy.

Moscow

vrach315@yandex.ruhttps://orcid.org/0000-0001-8124-109XКарселадзеН. Д.KarseladzeN. D.

Карселадзе Наталья Джимшеровна - к. м. н., врач-терапевт.

Московская область

Karseladze Natalia D. - PhD Med, general practitioner.

Moscow

karseladze@yandex.ruФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава РоссииРоссияPirogov Russian National Research Medical UniversityRussian FederationМедицинский центр аэропорта Московского авиационного узлаРоссияMedical Center of the Airport of the MOWRussian Federation202413052024013«Современная поликлиника» (1)1420Copyright © Орлова Н.В., Карселадзе Н.Д., 20242024Орлова Н.В., Карселадзе Н.Д.Orlova N.V., Karseladze N.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3715

Анемия хронических заболеваний является одним из самых распространенных заболеваний и оказывает значительное влияние на прогноз и смертность. В статье рассматриваются актуальность, патогенез, клинические проявления, лабораторная диагностика, лечение анемии хронических заболеваний. Лечение анемии зависит от степени тяжести и заболевания, осложнением которого она является. Рассматривается анемия при онкологических заболеваниях, хронической болезни почек, хронической сердечной недостаточности, циррозе печени, целиакии и др. Терапия, направленная на восполнение дефицита железа, включает переливание эритроцитарной массы, стимуляторы эритропоэтина, железосодержащие препараты. По данным обзора литературы представлена информация об особенностях ведения больных с анемией при различных хронических заболеваниях, дан обзор современного подхода к ферротерапии и ее осложнениям. Представлена информация о новой форме перорального железа – сукросомальное железо (СидерАЛ® Форте), которое хорошо переносится и обладает высокой биодоступностью. Приведен обзор клинических исследований, подтверждающих эффективность и безопасность применения перорального сукросомального железа.

Anemia of chronic diseases is one of the most common diseases and has a significant impact on prognosis and mortality. The article discusses the relevance, pathogenesis, clinical manifestations, laboratory diagnostics, and treatment of anemia of chronic diseases. The treatment of anemia depends on the severity and the disease of which it is a complication. Anemia is considered in oncological diseases, chronic kidney disease, chronic heart failure, cirrhosis of the liver, celiac disease, etc. Therapy aimed at replenishing iron deficiency includes transfusion of erythrocyte mass, erythropoietin stimulants, iron-containing drugs. According to the literature review, information is provided on the peculiarities of managing patients with anemia in various chronic diseases, an overview of the modern approach to ferrotherapy and its complications is given. Information is provided on a new form of oral iron – Sucrosomal iron (SiderAL Forte), which is well tolerated and has high bioavailability. A review of clinical studies confirming the efficacy and safety of oral Sucrosomal iron is presented.

анемияхронические заболеваниялечениепрепараты железасукросомальное железоanemiachronic diseasestreatmentiron preparationssucrosomal ironReferencesPoggiali E, Migone De Amicis M, Motta I. Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases. Eur. J. Intern. Med. 2014 Jan; 25 (1): 12–7. DOI: 10.1016/j.ejim.2013.07.011Poggiali E, Migone De Amicis M, Motta I. Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases. Eur. J. Intern. Med. 2014 Jan; 25 (1): 12–7. DOI: 10.1016/j.ejim.2013.07.011Clerico M, Tempia P, Guala A, Fasolo G, Lucca U. Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study. Haematologica. 2009 Jan; 94 (1): 22–8. DOI: 10.3324/haematol.13449Clerico M, Tempia P, Guala A, Fasolo G, Lucca U. Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study. Haematologica. 2009 Jan; 94 (1): 22–8. DOI: 10.3324/haematol.13449Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood. 2010 May 6; 115 (18): 3810–6. DOI: 10.1182/blood-2009–02–201087Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood. 2010 May 6; 115 (18): 3810–6. DOI: 10.1182/blood-2009–02–201087Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997 Jul 17; 337 (3): 141–7. DOI: 10.1056/NEJM199707173370301Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997 Jul 17; 337 (3): 141–7. DOI: 10.1056/NEJM199707173370301Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009 May; 75 (9): 976–81. DOI: 10.1038/ki.2009.21Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009 May; 75 (9): 976–81. DOI: 10.1038/ki.2009.21Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl. J. Med. 2009 Nov 19; 361 (21): 2019–32. DOI: 10.1056/NEJMoa0907845Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU et al. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl. J. Med. 2009 Nov 19; 361 (21): 2019–32. DOI: 10.1056/NEJMoa0907845Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012 Apr; 87 (4): 392–400. DOI: 10.1002/ajh.23110Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012 Apr; 87 (4): 392–400. DOI: 10.1002/ajh.23110Kellum J. A. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury/ Kidney international supplements. 2012; 2. (1): 1–138.Kellum J. A. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury/ Kidney international supplements. 2012; 2. (1): 1–138.Madu AJ, Ughasoro MD. Anaemia of Chronic Disease: An In-Depth Review. Med Princ Pract. 2017; 26 (1): 1–9. DOI: 10.1159/000452104Madu AJ, Ughasoro MD. Anaemia of Chronic Disease: An In-Depth Review. Med Princ Pract. 2017; 26 (1): 1–9. DOI: 10.1159/000452104Н. И. Стуклов, А. А. Гуркина, М. С. Ковальчук, Н. Д. Кислый. Современные представления о механизмах всасывания железа: активаторы, ингибиторы, регуляция, новые возможности оптимизации. Терапия. 2023; 9 (4): 119–129.N. I. Stukalov, A. A. Gurkina, M. S. Kovalchuk, N. D. Kislyi. Modern ideas about the mechanisms of iron absorption: activators, inhibitors, regulation, new optimization possibilities.Therapy. 2023; 9 (4): 119–129.Gomez-Ramirez S., Brilli E., Tarantino G., Munoz M. Sucrosomial® iron: A new generation iron for improving oral supplementation. Pharmaceuticals (Basel). 2018; 11 (4): 97. DOI: 10.3390/ph11040097Gomez-Ramirez S., Brilli E., Tarantino G., Munoz M. Sucrosomial® iron: A new generation iron for improving oral supplementation. Pharmaceuticals (Basel). 2018; 11 (4): 97. DOI: 10.3390/ph11040097Malhotra J., Garg R., Malhotra N., Agrawal P. Oral Liposomal Iron: A Treatment Proposal for Anemia. World J. Anemia. 2017; 1 (4): 1–6. DOI: 10.5005/jp-journals-10065–0019Malhotra J., Garg R., Malhotra N., Agrawal P. Oral Liposomal Iron: A Treatment Proposal for Anemia. World J. Anemia. 2017; 1 (4): 1–6. DOI: 10.5005/jp-journals-10065–0019Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol. Dial. Transplant. 2015 Apr; 30 (4): 645–52. DOI: 10.1093/ndt/gfu357Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol. Dial. Transplant. 2015 Apr; 30 (4): 645–52. DOI: 10.1093/ndt/gfu357Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017 Sep; 25 (9): 2779–2786. DOI: 10.1007/s00520–017–3690-zMafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017 Sep; 25 (9): 2779–2786. DOI: 10.1007/s00520–017–3690-zBarni S, Gascòn P, Petrelli F, García-Erce JA, Pedrazzoli P, Rosti G, Giordano G, Mafodda A, Múñoz M. Position paper on management of iron deficiency in adult cancer patients. Expert Rev Hematol. 2017 Aug; 10 (8): 685–695. DOI: 10.1080/17474086.2017.1343140Barni S, Gascòn P, Petrelli F, García-Erce JA, Pedrazzoli P, Rosti G, Giordano G, Mafodda A, Múñoz M. Position paper on management of iron deficiency in adult cancer patients. Expert Rev Hematol. 2017 Aug; 10 (8): 685–695. DOI: 10.1080/17474086.2017.1343140Romano A, Conticello C, Motta G, Caruso AL, Chiarenza A, Figuera A et al. Oral Sucrosomial® iron supplementation in patients affected by Hodgkin lymphoma with mild anemia before chemotherapy: an observational study. Exp. Rev. Hematol. 2016; 9 (S 1): 30–31.Romano A, Conticello C, Motta G, Caruso AL, Chiarenza A, Figuera A et al. Oral Sucrosomial® iron supplementation in patients affected by Hodgkin lymphoma with mild anemia before chemotherapy: an observational study. Exp. Rev. Hematol. 2016; 9 (S 1): 30–31.Indriolo A, Ravelli P. Comparison between liposomial iron and ferrous sulfate in patients with iron deficiency anemia and inflammatory bowel disease. A pilot controlled study. J. Crohn’s Colitis. 2014 Feb; 8 (S 1): S 289.Indriolo A, Ravelli P. Comparison between liposomial iron and ferrous sulfate in patients with iron deficiency anemia and inflammatory bowel disease. A pilot controlled study. J. Crohn’s Colitis. 2014 Feb; 8 (S 1): S 289.Nasutia A, Sagristanib M, Sessa F. Oral Sucrosomial® iron (Sideral® Forte) is effective and well tolerated in elderly patients affected by iron deficiency anemia of various origins. Exp. Rev. Hematol. 2016; 9 (S 1): 38, 39.Nasutia A, Sagristanib M, Sessa F. Oral Sucrosomial® iron (Sideral® Forte) is effective and well tolerated in elderly patients affected by iron deficiency anemia of various origins. Exp. Rev. Hematol. 2016; 9 (S 1): 38, 39.Elli L, Ferretti F, Branchi F, Tomba C, Lombardo V, Scricciolo A et al. Sucrosomial Iron Supplementation in Anemic Patients with Celiac Disease Not Tolerating Oral Ferrous Sulfate: A Prospective. Study. Nutrients. 2018 Mar 9; 10 (3): 330. DOI: 10.3390/nu10030330Elli L, Ferretti F, Branchi F, Tomba C, Lombardo V, Scricciolo A et al. Sucrosomial Iron Supplementation in Anemic Patients with Celiac Disease Not Tolerating Oral Ferrous Sulfate: A Prospective. Study. Nutrients. 2018 Mar 9; 10 (3): 330. DOI: 10.3390/nu10030330Gómez-Ramírez S, Brilli E, Tarantino G, Girelli D, Muñoz M. Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency. Pharmaceuticals (Basel). 2023 Jun 6; 16 (6): 847. DOI: 10.3390/ph16060847Gómez-Ramírez S, Brilli E, Tarantino G, Girelli D, Muñoz M. Sucrosomial® Iron: An Updated Review of Its Clinical Efficacy for the Treatment of Iron Deficiency. Pharmaceuticals (Basel). 2023 Jun 6; 16 (6): 847. DOI: 10.3390/ph16060847Ponikowski P., Voors A. A., Anker S. D., Bueno H., Cleland J. G.F., Coats A. J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016; 37: 2129–2200. DOI: 10.1093/eurheartj/ehw128Ponikowski P., Voors A. A., Anker S. D., Bueno H., Cleland J. G.F., Coats A. J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016; 37: 2129–2200. DOI: 10.1093/eurheartj/ehw128Tim Goodnough L, Comin-Colet J, Leal-Noval S, Ozawa S, Takere J, Henry D et al. Management of anemia in patients with congestive heart failure. Am. J. Hematol. 2017 Jan; 92 (1): 88–93. DOI: 10.1002/ajh.24595Tim Goodnough L, Comin-Colet J, Leal-Noval S, Ozawa S, Takere J, Henry D et al. Management of anemia in patients with congestive heart failure. Am. J. Hematol. 2017 Jan; 92 (1): 88–93. DOI: 10.1002/ajh.24595Lewis G. D., Malhotra R., Hernandez A. F., McNulty S.E., Smith A., Felker G. M. et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF randomized clinical trial. JAMA. 2017; 317: 1958–1966. DOI: 10.1001/jama.2017.5427Lewis G. D., Malhotra R., Hernandez A. F., McNulty S.E., Smith A., Felker G. M. et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF randomized clinical trial. JAMA. 2017; 317: 1958–1966. DOI: 10.1001/jama.2017.5427Karavidas A., Troganis E., Lazaros G., Balta D., Karavidas I.-N., Polyzogopoulou E. et al. Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: A non-randomized, open-label, proof-of-concept study. Eur. J. Heart Fail. 2021; 23: 593–597. DOI: 10.1002/ejhf.2092Karavidas A., Troganis E., Lazaros G., Balta D., Karavidas I.-N., Polyzogopoulou E. et al. Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: A non-randomized, open-label, proof-of-concept study. Eur. J. Heart Fail. 2021; 23: 593–597. DOI: 10.1002/ejhf.2092Гуркина А. А., Стуклов Н. И., Кислый Н. Д., Гимадиев Р. Р., Стрельников А. А. Новые возможности патогенетической коррекции анемии при хронической сердечной недостаточности. Клиническая медицина. 2023; 101 (7–8): 387–394. http://dx.doi.org/10.30629/0023–2149–2023–101–7–8–387–394Gurkina A. A., Stuklov N. I., Kislyi N. D., Gimadiev R. R., Strelnikov A. A. New possibilities of pathogenetic correction of anemia in chronic heart failure. Clinical medicine. 2023; 101 (7–8): 387–394. DOI: http://dx.doi.org/10.30629/0023–2149–2023–101–7–8–387–394Ghio S., Fortuni F., Capettini A. C., Scelsi L., Greco A., Vullo E. et al. Iron deficiency in pulmonary arterial hypertension: Prevalence and potential usefulness of oral supplementation. Acta Cardiol. 2021; 76: 162–167. DOI: 10.1080/00015385.2019.1694760Ghio S., Fortuni F., Capettini A. C., Scelsi L., Greco A., Vullo E. et al. Iron deficiency in pulmonary arterial hypertension: Prevalence and potential usefulness of oral supplementation. Acta Cardiol. 2021; 76: 162–167. DOI: 10.1080/00015385.2019.1694760

The authors declare that there are no conflicts of interest present.